Needham analyst Michael Matson (NYSE:MATX) reiterated a Buy rating on Medtronic (NYSE:MDT) on Thursday, setting a price target of $146, which is approximately 15.63% above the present share price of $126.27.
Matson expects Medtronic to post earnings per share (EPS) of $0.94 for the second quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Medtronic, with an average price target of $139.18.
The analysts price targets range from a high of $153 to a low of $130.
In its latest earnings report, released on 01/31/2021, the company reported a quarterly revenue of $7.78 billion and a net profit of $1.48 billion. The company's market cap is $170.22 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.9% and a 67.42% success rate.
Founded in 1949, Medtronic Plc, a medical technology company, develops, manufactures, distributes, and sells device-based medical therapies and services worldwide. It operates through four segments, including Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The company is headquartered in Dublin, Ireland.